Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC st...( WEST CHESTER PA Sept. 11 / Diagno...),Health

WEST CHESTER, PA, Sept. 11 /PRNewswire-FirstCall/ - DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure, announced corporate sponsorship of the Colon Cancer Alliance's (CCA) inaugural charity event the "Undy 5,000: A Brief Run to Fight Colon Cancer" being held in Philadelphia, PA, on September 27, 2008. The CCA is an advocacy group that focuses on the concerns of the colon cancer patient community. DiagnoCure will sponsor the race at the "Championship Level" to coincide with the CLIA certification of their molecular diagnostic laboratory and start of commercialization of the Company's Previstage(TM) GCC Colorectal Cancer Staging Test, which was announced recently.

"Through proactive outreach and creative events such as the Undy 5,000, we can educate patients about the importance of properly staging colorectal cancer and how Previstage(TM) GCC can help physicians and patients in making critical treatment decisions" stated John Schafer, President and CEO of DiagnoCure.

The American Cancer Society estimates there will be approximately 154,000 patients diagnosed with colorectal cancer in the U.S. each year. Colorectal cancer is the second leading cause of cancer death among men and women in the United States and Canada (after lung cancer). The Undy 5,000 salutes the brave men and women along with their families battling this disease.

"The CCA is very grateful to have DiagnoCure as a corporate sponsor. The Undy 5,000 is a great way for new and inventive technologies such as Previstage(TM) GCC to gain exposure with the colorectal cancer community" stated Tim Turnham, CEO Colon Cancer Alliance.

About Previstage(TM) GCC

Every year in North America, 174,000 people are diagnosed with colorectal cancer, and 142,000 colorectal cancer surgeries are performed. Staging a patient with colorectal cancer is crucial because it determines the patient's course of treatment after the surgery. Current standard of care requires that pathol
'/>"/>